Edition:
United Kingdom

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

160.22USD
18 Jan 2019
Change (% chg)

$3.66 (+2.34%)
Prev Close
$156.56
Open
$157.77
Day's High
$160.36
Day's Low
$156.38
Volume
865,768
Avg. Vol
643,050
52-wk High
$197.00
52-wk Low
$125.84

Chart for

About

Allergan plc is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US... (more)

Overall

Beta: 1.17
Market Cap(Mil.): $69,117.80
Shares Outstanding(Mil.): 334.31
Dividend: 0.70
Yield (%): 1.35

Financials

  AGN.N Industry Sector
P/E (TTM): -- 30.48 33.71
EPS (TTM): -11.66 -- --
ROI: -3.08 14.98 14.48
ROE: -5.61 16.31 15.99

Health Canada places restrictions on Allergan's fibroid treatment Esmya

Canada's health regulator on Friday said it was restricting the use of Allergan Plc's uterine fibroid treatment Esmya after discovering a risk of serious liver injury from the drug.

11 Jan 2019

Health Canada places restrictions on Allergan's fibroid treatment Esmya

Jan 11 Canada's health regulator on Friday said it was restricting the use of Allergan Plc's uterine fibroid treatment Esmya after discovering a risk of serious liver injury from the drug.

11 Jan 2019

Allergan stops sale of textured breast implants in Europe, shares sink

NEW YORK Drugmaker Allergan Plc said on Wednesday it would take its textured breast implants off the market in Europe, a day after a French regulatory body ordered a recall of the implants, which have been linked to a rare form of cancer.

19 Dec 2018

Allergan stops sale of textured breast implants in Europe, shares sink

NEW YORK Drugmaker Allergan Plc said on Wednesday it would take its textured breast implants off the market in Europe, a day after a French regulatory body ordered a recall of the implants, which have been linked to a rare form of cancer.

19 Dec 2018

UPDATE 2-Allergan stops sale of textured breast implants in Europe, shares sink

NEW YORK, Dec 19 Drugmaker Allergan Plc said on Wednesday it would take its textured breast implants off the market in Europe, a day after a French regulatory body ordered a recall of the implants, which have been linked to a rare form of cancer.

19 Dec 2018

CORRECTED-UPDATE 1-Allergan stops sales of textured breast implants in Europe

PARIS, Dec 19 Drugmaker Allergan said on Wednesday it would take its textured breast implants off the market in Europe, a day after a French regulatory body ordered the recall of the implants, which have been linked to a rare form of cancer.

19 Dec 2018

Allergan stops sales in Europe of breast implants linked to cancer

PARIS, Dec 19 Breast implants made by drugmaker Allergan, which have been linked to a rare form of cancer, are being taken off the market in Europe, said a French regulatory body.

19 Dec 2018

Revance Therapeutics' Botox rival succeeds in late-stage trial

A potential rival for Allergan Plc's blockbuster Botox has passed a late-stage study, putting drug developer Revance Therapeutics Inc on course to file for U.S. marketing approval next year.

04 Dec 2018

UPDATE 2-Revance Therapeutics' Botox rival succeeds in late-stage trial

Dec 4 A potential rival for Allergan Plc's blockbuster Botox has passed a late-stage study, putting drug developer Revance Therapeutics Inc on course to file for U.S. marketing approval next year.

04 Dec 2018

Allergan says offers undervalue business units for sale, shares fall

Allergan Plc on Tuesday expressed disappointment in early offers from potential buyers for business units it has been trying to sell, and its shares fell more than 6 percent.

30 Oct 2018

Earnings vs. Estimates